Table 6 Summary of relationship of RDI with treatment outcomes and safety profile (SAS)
Pazopanib N = 190 | |||
|---|---|---|---|
Mean RDI (SD) | 79.4 (21.04) | ||
Median RDI (range) | 81.9 (32.5–100.0) | ||
RDI < 85%, n (%) | 99 (52.1) | ||
RDI ≥ 85%, n (%) | 91 (47.9) | ||
Reduced RDI (< 100%), n (%) | 120 (63.2) | ||
Treatment response categories | Mean RDI < 85% n = 73 | Mean RDI ≥ 85% n = 55 | Total n = 128 |
ORR, n (%) | 14 (19.2) | 18 (32.7) | 32 (25.0) |
Mean RDI (SD) | 63.7 (12.8) | 98.2 (3.4) | 83.1 (19.4) |
Complete response, n (%) | 1 (1.4) | 3 (5.5) | 4 (3.1) |
Mean RDI (SD) | 75.0 (NE) | 97.9 (1.8) | 92.2 (11.6) |
Partial response, n (%) | 13 (17.8) | 15 (27.3) | 28 (21.9) |
Mean RDI (SD) | 62.8 (12.9) | 98.2 (3.7) | 81.8 (20.1) |
Stable disease, n (%) | 32 (43.8) | 24 (43.6) | 56 (43.8) |
Mean RDI (SD) | 61.4 (12.9) | 98.1 (3.6) | 77.1 (20.8) |
Progressive disease, n (%) | 27 (37.0) | 13 (23.6) | 40 (31.3) |
Mean RDI (SD) | 60.8 (14.9) | 98.5 (3.2) | 73.1 (21.7) |
AE categories | n = 99 | n = 91 | n = 190 |
Any AE, n (%) | 97 (98.0) | 70 (76.9) | 167 (87.9) |
Mean RDI (SD) | 61.5 (13.7) | 98.2 (3.2) | 76.9 (21.1) |
Serious AE, n (%) | 38 (38.4) | 27 (29.7) | 65 (34.2) |
Mean RDI (SD) | 61.0 (14.3) | 97.8 (3.7) | 76.3 (21.4) |